Summary
The AI response claims the provided text is the boxed warning and is supported by the label excerpts, but the supplied label excerpts do not include the boxed warning text itself and instead focus on thyroid C-cell tumor risk. No other provided claims (side effects, depression/anxiety, hypoglycemia/URI symptoms, urgent care triggers, counseling) are evaluated against the supplied label excerpts, creating major context mismatch. Therefore alignment cannot be verified for the broader content, and the boxed-warning framing is not fully demonstrable from the provided excerpts.
Category Scores
Accurate Statements
Your provided text is the boxed warning about thyroid C-cell tumors (including medullary thyroid carcinoma risk), based on rodent data and contraindications in humans at risk (personal/family history of MTC or MEN 2).
Supported by label excerpts describing thyroid C-cell tumors in rats with unknown human relevance (5.1) and contraindications in patients with personal/family history of MTC or MEN 2 (4), with carcinogenesis study details (13.1) and patient counseling/symptoms (17).
Unsupported Statements
Zepbound’s common side effects include nausea, diarrhea, constipation, decreased appetite, vomiting, and fatigue.
Not supported by the provided label excerpts (none of Sections 4, 5.1, 13.1, or 17 contain these common side-effect details).
Depression and anxiety are not among the most common side effects reported for Zepbound.
Not supported by the provided label excerpts.
Zepbound can indirectly affect how someone feels by changing appetite, eating patterns, hydration status, sleep, and overall physical well-being.
Not supported by the provided label excerpts.
Some weight-loss medicines can contribute to low blood sugar, especially in people taking insulin or insulin secretagogues.
Not supported by the provided label excerpts.
Hypoglycemia can feel like anxiety (shakiness, sweating, racing heart).
Not supported by the provided label excerpts.
Hypoglycemia can also worsen mood.
Not supported by the provided label excerpts.
The risk of hypoglycemia with Zepbound depends on other medications, including diabetes drugs taken with Zepbound.
Not supported by the provided label excerpts.
Get urgent medical care if there are thoughts of self-harm or suicide.
Not supported by the provided label excerpts.
Get urgent medical care if there is severe agitation, confusion, or inability to function.
Not supported by the provided label excerpts.
Get urgent medical care if there are signs of severe allergic reaction (swelling, trouble breathing, widespread rash).
Partially related to serious hypersensitivity/allergy being reported in contraindications section 4, but the specific urgent-care trigger wording and symptom set is not shown in the provided excerpts.
Worsening depression or significant anxiety without emergencies should prompt contacting the prescriber promptly.
Not supported by the provided label excerpts.
A prescriber may adjust the dose, review other medications, or evaluate other causes when depression or anxiety worsens.
Not supported by the provided label excerpts.
If Zepbound is contributing, symptoms often improve after addressing the underlying issue (for example, dehydration, poor intake, or dose-related intolerance).
Not supported by the provided label excerpts.
People should not stop or change the Zepbound dose without clinician guidance.
Not supported by the provided label excerpts.
Mood symptoms can have many causes and treatment plan adjustment may be needed rather than abrupt discontinuation.
Not supported by the provided label excerpts.
The most current safety label details and documented adverse-event reporting can be found in Zepbound’s official prescribing information or safety resources.
Not supported within the provided label excerpts (this is a general statement and not verifiable against the supplied text).
Contradictions
Important Omissions
No label excerpt was provided that explicitly contains the boxed warning text itself; only supportive narrative from Section 5.1/4/13.1/17 was supplied. If the evaluation is meant to confirm that the exact 'provided text' equals the boxed warning, that equivalence cannot be verified from the excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported statement in the AI output concerns the boxed-warning topic of thyroid C-cell tumors and related contraindications/symptoms. However, many additional safety-related claims (side effects, hypoglycemia interpretation, psychiatric symptom triage) are not supported by the provided label excerpts, so accuracy for those claims cannot be confirmed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims in the AI output (side effects, depression/anxiety, hypoglycemia and symptom interpretation, psychiatric and allergic-reaction triage, and dosing-change guidance) are not supported by the provided label excerpts.
Suggested Improvement
Limit the response to the thyroid C-cell tumor boxed-warning topic and its label-supported elements (unknown human relevance, contraindications for MTC/MEN 2, and counseling symptoms/reporting), and do not assert other common side effects, hypoglycemia/psychiatric symptom guidance, or specific urgent-care triggers unless those exact sections are provided in the label excerpts.